Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/24 10:00:16 pm
60.75 USD   -0.74%
08:03p MERCK : Seminole Management Co. Inc. Invests $19,783,000 in Merck & ..
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to..
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2012 | 12:03am CEST
   By Peter Loftus 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
08:03p MERCK : Seminole Management Co. Inc. Invests $19,783,000 in Merck & Co. (MRK)
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
10/20 MERCK : Studies from Merck Research Labs in the Area of Thrombosis Reported (Dif..
10/20MERCK & CO., INC. : quaterly earnings release
10/19 MERCK : Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antivi..
More news
Sector news : Pharmaceuticals - NEC
04:32pDJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
12:46pDJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05:30p Notable earnings before Tuesday?s open
10:11a BIOTECH FORUM DAILY DIGEST : Election Worries Overblown? Spotlight On Akorn
07:01a Glaxo submits BLA for shingles vaccine in U.S.
10/22 FDA OKs Merck's bezlotoxumab to reduce recurrence of C. diff infection in cer..
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
Financials ($)
Sales 2016 39 696 M
EBIT 2016 13 597 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,97%
P/E ratio 2016 30,00
P/E ratio 2017 19,78
EV / Sales 2016 4,40x
EV / Sales 2017 4,30x
Capitalization 169 231 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.87%169 231
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
More Results